[1]谭思华 周晓莉.非酒精性脂肪肝与冠状动脉粥样硬化及炎症的研究进展[J].心血管病学进展,2023,(5):439.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.013]
　TAN Sihua,ZHOU Xiaoli.Association of Non-Alcoholic Fatty Liver Disease with Coronary Atherosclerosis and Inflammation[J].Advances in Cardiovascular Diseases,2023,(5):439.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.013]
点击复制

非酒精性脂肪肝与冠状动脉粥样硬化及炎症的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年5期
页码:
439
栏目:
综述
出版日期:
2023-05-25

文章信息/Info

Title:
Association of Non-Alcoholic Fatty Liver Disease with Coronary Atherosclerosis and Inflammation
作者:
谭思华 周晓莉
(重庆医科大学附属第一医院心血管内科,重庆 400016)
Author(s):
TAN Sihua; ZHOU Xiaoli
(Department of Cardiology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
关键词:
心血管疾病; 非酒精性脂肪性肝病; 冠状动脉粥样硬化; 全身炎症; 胰岛素抵抗; 冠状动脉钙化; 高危斑块
Keywords:
Cardiovascular disease; Non-alcoholic fatty liver disease; Coronary atherosclerosis; Systemic inflammation; Insulin resistance; coronary calcification; high-risk plaque
DOI:
10.16806/j.cnki.issn.1004-3934.2023.05.013
摘要:
心血管疾病是人类健康的重要问题，随着对非酒精性脂肪性肝病（NAFLD）的深入研究，近年来发现NAFLD与动脉粥样硬化性心血管疾病密切相关，可能会增加冠状动脉钙化及高危斑块的风险。越来越多的证据表明，NAFLD不仅是标志物，还可能参与冠状动脉粥样硬化的发病机制，包括全身炎症、胰岛素抵抗以及血脂异常等。现就近年来对NAFLD与冠状动脉粥样硬化关系认识的进展进行综述，以期提高对早期冠状动脉粥样硬化危险因素的识别。
Abstract:
Cardiovascular disease is an important problem for human health. With the in-depth research on non-alcoholic fatty liver disease(NAFLD),it has been found that NAFLD is closely related to atherosclerotic cardiovascular disease in recent years,which may increase the risk of coronary artery calcification and high-risk plaque. Accumulating evidence suggests that NAFLD is not only a marker,but may also be involved in the pathogenesis of coronary atherosclerosis,including systemic inflammation,insulin resistance and dislipidemia. This article reviews recent advances in the understanding of the relationship between NAFLD and coronary atherosclerosis,with the hope of improving the identification of risk factors for early coronary atherosclerosis.

参考文献/References:

[1] Lozano R,Naghavi M,Foreman K,et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet,2012,380(9859):2095-2128.

[2] Benjamin EJ,Muntner P,Alonso A,et al. Heart Disease and Stroke Statistics-2019 Update:a report from the American Heart Association[J]. Circulation,2019,139(10):e56-e528.

[3] Younossi Z,Anstee QM,Marietti M,et al. Global burden of NAFLD and NASH:trends,predictions,risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2018,15(1):11-20.

[4] Zhou YY,Zhou XD,Wu SJ,et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis:a systematic review and meta-analysis[J]. Hepatol Commun,2018,2(4):376- 392.

[5] Eslam M,Sanyal AJ,George J,et al. NAFLD:a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology,2020,158(7):1999-2014.

[6] Mantovani A,Csermely A,Petracca G,et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events:an updated systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2021,6(11):903-913.

[7] Niriella MA,Kasturiratne A,Beddage TU,et al. Metabolic syndrome,but not non-alcoholic fatty liver disease,increases 10-year mortality:a prospective,community-cohort study[J]. Liver Int,2020,40(1):101- 106.

[8] Long MT,Zhang X,Xu H,et al. Hepatic fibrosis associates with multiple cardiometabolic disease risk factors:The Framingham Heart Study[J]. Hepatology,2021,73(2):548-559.

[9] Targher G,Byrne CD,Tilg H. NAFLD and increased risk of cardiovascular disease:clinical associations,pathophysiological mechanisms and pharmacological implications[J]. Gut,2020,69(9):1691-1705.

[10] Lin A,Wong ND,Razipour A,et al. Metabolic syndrome,fatty liver,and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events:a prospective study[J]. Cardiovasc Diabetol,2021,20(1):27.

[11] Knuuti J,Wijns W,Saraste A,et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J,2020,41(3):407-477.

[12] Kasper P,Martin A,Lang S,et al. NAFLD and cardiovascular diseases:a clinical review[J]. Clin Res Cardiol,2021,110(7):921-937.

[13] Arab JP,Arrese M,Trauner M.Recent insights into the pathogenesis of nonalcoholic fatty liver disease[J]. Annu Rev Pathol,2018,13:321-350.

[14] Ding X,Wang X,Wu J,et al. Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular diseases:a meta-analysis of cohort studies[J]. Cardiovasc Diabetol,2021,20(1):76.

[15] Baydar O,Kilic A,Okcuoglu J,et al. The triglyceride-glucose index,a predictor of insulin resistance,is associated with subclinical atherosclerosis[J]. Angiology,2021,72(10):994-1000.

[16] Zhao S,Yu S,Chi C,et al. Association between macro- and microvascular damage and the triglyceride glucose index in community-dwelling elderly individuals:the Northern Shanghai Study[J]. Cardiovasc Diabetol,2019,18(1):95.

[17] Singhal A,Chauhan A,Goyal P,et al. Transthyretin—A novel biomarker for insulin resistance and atherosclerosis risk in prediabetics[J]. J Assoc Physicians India,2021,69(11):11-12.

[18] Fabbrini E,Sullivan S,Klein S. Obesity and nonalcoholic fatty liver disease:biochemical,metabolic,and clinical implications[J]. Hepatology,2010,51(2):679- 689.

[19] Solinas G,Naugler W,Galimi F,et al. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates[J]. Proc Natl Acad Sci U S A,2006,103(44):16454-16459.

[20] Younossi ZM,Koenig AB,Abdelatif D,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence,incidence,and outcomes[J]. Hepatology,2016,64(1):73-84.

[21] Lee JH,Lee HS,Cho AR,et al. Non-alcoholic fatty liver disease is an independent risk factor for LDL cholesterol target level[J]. Int J Environ Res Public Health,2021,18(7):3442.

[22] Ference BA,Ginsberg HN,Graham I,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic,epidemiologic,and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J,2017,38(32):2459-2472.

[23] Negre-Salvayre A,Guerby P,Gayral S,et al. Role of reactive oxygen species in atherosclerosis:lessons from murine genetic models[J]. Free Radic Biol Med,2020,149:8-22.

[24] Gianazza E,Brioschi M,Martinez Fernandez A,et al. Lipid peroxidation in atherosclerotic cardiovascular diseases[J]. Antioxid Redox Signal,2021,34(1):49-98.

[25] Videla LA,Rodrigo R,Orellana M,et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients[J]. Clin Sci(Lond),2004,106(3):261-268.

[26] K?ro?lu E,Canbakan B,Atay K,et al. Role of oxidative stress and insulin resistance in disease severity of non-alcoholic fatty liver disease[J]. Turk J Gastroenterol,2016,27(4):361-366.

[27] Fiorelli S,Porro B,Cosentino N,et al. Activation of Nrf2/HO-1 pathway and human atherosclerotic plaque vulnerability:an in vitro and in vivo study[J]. Cells,2019,8(4):356.

[28] Simsek MA,Korkmaz B,Ezici A,et al. The association between serum heme oxygenase-1 levels and coronary SYNTAX score[J]. Cardiology,2021,146(3):288-294.

[29] Wen Y,Leake DS. Low density lipoprotein undergoes oxidation within lysosomes in cells[J]. Circ Res,2007,100(9):1337- 1343.

[30] Montarello NJ,Nguyen MT,Wong DTL,et al. Inflammation in coronary atherosclerosis and its therapeutic implications[J]. Cardiovasc Drugs Ther,2022,36(2):347-362.

[31] Almuwaqqat Z,Hwan Kim J,Garcia M,et al. Associations between inflammation,cardiovascular regenerative capacity,and cardiovascular events:a cohort study[J]. Arterioscler Thromb Vasc Biol,2021,41(11):2814-2822.

[32] Libby P. Interleukin-1 beta as a target for atherosclerosistherapy:biological basis of CANTOS?andbeyond[J]. J Am Coll Cardiol,2017,70(18):2278-2289.

[33] Duan Y,Pan X,Luo J,et al. Association of inflammatory cytokines with non-alcoholic fatty liver disease[J]. Front Immunol,2022,13:880298.

[34] Ridker PM,Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease[J]. Circ Res,2021,128(11):1728-1746.

[35] Simon TG,Trejo MEP,McClelland R,et al. Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease:results from the Multi-Ethnic Study of Atherosclerosis[J]. Int J Cardiol,2018,259:198-204.

[36] Fricker ZP,Pedley A,Massaro JM,et al. Liver fat is associated with markers of inflammation and oxidative stress in analysis of data from the Framingham Heart Study[J]. Clin Gastroenterol Hepatol,2019,17(6):1157-1164.

[37] Khoury T,Mari A,Nseir W,et al. Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease[J]. Eur J Gastroenterol Hepatol,2019,31(9):1110-1115.

[38] Chen LZ,Jing XB,Wu CF,et al. Nonalcoholic fatty liver disease-associated liver fibrosis is linked with the severity of coronary artery disease mediated by systemic inflammation[J]. Dis Markers,2021,2021:6591784.

[39] Dogru T,Kirik A,Gurel H,et al. The evolving role of fetuin-A in nonalcoholic fatty liver disease:an overview from liver to the heart[J]. Int J Mol Sci,2021,22(12):6627.

[40] Pan X,Kaminga AC,Chen J,et al. Fetuin-A and fetuin-B in non-alcoholic fatty liver disease:a meta-analysis and meta-regression[J]. Int J Environ Res Public Health,2020,17(8):2735.

[41] Afrisham R,Paknejad M,Ilbeigi D,et al. Positive correlation between circulating fetuin-A and severity of coronary artery disease in men[J]. Endocr Metab Immune Disord DrugTargets,2021,21(2):338-344.

[42] Mori K,Emoto M,Inaba M. Fetuin-A and the cardiovascular system[J]. Adv Clin Chem,2012,56:175-195.

[43] Chen PY,Qin L,Li G,et al. Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis[J]. Nat Metab,2019,1(9):912-926.

[44] Aron-Wisnewsky J,Vigliotti C,Witjes J,et al. Gut microbiota and human NAFLD:disentangling microbial signatures from metabolic disorders[J]. Nat Rev Gastroenterol Hepatol,2020,17(5):279-297.

[45] Ramírez-Macías I,Orenes-Pi?ero E,Camelo-Castillo A,et al. Novel insights in the relationship of gut microbiota and coronary artery diseases[J]. Crit Rev Food Sci Nutr,2022,62(14):3738-3750.

[46] Haghikia A,Li XS,Liman TG,et al. Gut microbiota-dependent trimethylamine N-oxide predicts risk of cardiovascular events in patients with stroke and is related to proinflammatory monocytes[J]. Arterioscler Thromb Vasc Biol,2018,38(9):2225-2235.

[47] Kim YS,Lee SH,Park SG,et al. Low levels of total and high-molecular-weight adiponectin may predict non-alcoholic fatty liver in Korean adults[J]. Metabolism,2020,103:154026.

[48] Gruzdeva O,Uchasova E,Dyleva Y,et al. Adipocytes directly affect coronary artery disease pathogenesis via induction of adipokine and cytokine imbalances[J]. Front Immunol,2019,10:2163.

[49] Stols-Gon?alves D,Hovingh GK,Nieuwdorp M,et al. NAFLD and atherosclerosis:two sides of the same dysmetabolic coin?[J]. Trends Endocrinol Metab,2019,30(12):891-902.

[50] Campbell PT,VanWagner LB,Colangelo LA,et al. Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife:CARDIA[J]. Liver Int,2020,40(5):1111-1120.

[51] Grandhi GR,Mirbolouk M,Dardari ZA,et al. Interplay of coronary artery calcium andrisk factors for predicting CVD/CHDmortality:The CAC Consortium[J]. JACC Cardiovasc Imaging,2020,13(5):1175-1186.

[52] Chang Y,Ryu S,Sung KC,et al. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification:evidence from the Kangbuk Samsung Health Study[J]. Gut,2019,68(9):1667-1675.

[53] Lee J,Kim HS,Cho YK,et al. Association between noninvasive assessment of liver fibrosis and coronary artery calcification progression in patients with nonalcoholic fatty liver disease[J]. Sci Rep,2020,10(1):18323.

[54] Kim SH,Park HY,Lee HS,et al. Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity[J]. Sci Rep,2020,10(1):1025.

[55] Lee SB,Park GM,Lee JY,et al. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis:an observational cohort study[J]. J Hepatol,2018,68(5):1018-1024.

[56] Park HE,Kwak MS,Kim D,et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification development:a longitudinal study[J]. J Clin Endocrinol Metab,2016,101(8):3134-3143.

[57] Ichikawa K,Miyoshi T,Osawa K,et al. Prognostic value of coronary computed tomographic angiography in patients with nonalcoholic fatty liver disease[J]. JACC Cardiovasc Imaging,2020,13(7):1628-1630.

[58] Ichikawa K,Miyoshi T,Osawa K,et al. Incremental prognostic value of non-alcoholic fatty liver disease over coronary computed tomography angiography findings in patients with suspected coronary artery disease[J]. Eur J Prev Cardiol,2022,28(18):2059-2066.

相似文献/References:

[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
　BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(5):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
　REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(5):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
　YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(5):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
　ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(5):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
　QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(5):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
　JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(5):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
　HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
　Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
　WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(5):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]

更新日期/Last Update: 2023-06-29